George Farmer
Stock Analyst at Scotiabank
(1.94)
# 3,065
Out of 4,900 analysts
77
Total ratings
37.21%
Success rate
-5.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SAGE Sage Therapeutics | Downgrades: Sector Perform | $12 → $9.2 | $9.17 | +0.33% | 6 | Jul 8, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $2.07 | -71.01% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $14.04 | +234.76% | 1 | Jun 13, 2025 | |
| ACLX Arcellx | Maintains: Sector Outperform | $133 → $93 | $68.14 | +36.48% | 2 | May 9, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $9.21 | +84.58% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $3.05 | +293.44% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $6.69 | +34.53% | 4 | Apr 10, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Sector Outperform | $3.15 → $1.4 | $0.27 | +412.82% | 2 | Mar 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $25.76 | +59.16% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $21.02 | +147.38% | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $78 → $80 | $56.62 | +41.29% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $127.50 | +75.69% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $30.70 | +232.25% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $6.13 | +63.13% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $554.71 | +28.90% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $6.56 | +250.61% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $3.74 | +434.76% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $21 → $41 | $1.78 | +2,203.37% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $39.59 | +91.97% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $2.57 | +405.84% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $31.58 | +245.16% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $68.25 | +27.47% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.11 | +1,463.98% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $0.83 | +4,701.34% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $44.06 | -38.72% | 3 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $89 → $75 | $129.35 | -42.02% | 3 | Apr 29, 2020 |
Sage Therapeutics
Jul 8, 2025
Downgrades: Sector Perform
Price Target: $12 → $9.2
Current: $9.17
Upside: +0.33%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $2.07
Upside: -71.01%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $14.04
Upside: +234.76%
Arcellx
May 9, 2025
Maintains: Sector Outperform
Price Target: $133 → $93
Current: $68.14
Upside: +36.48%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $9.21
Upside: +84.58%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.05
Upside: +293.44%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $6.69
Upside: +34.53%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Sector Outperform
Price Target: $3.15 → $1.4
Current: $0.27
Upside: +412.82%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $25.76
Upside: +59.16%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $21.02
Upside: +147.38%
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $56.62
Upside: +41.29%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $127.50
Upside: +75.69%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $30.70
Upside: +232.25%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $6.13
Upside: +63.13%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $554.71
Upside: +28.90%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $6.56
Upside: +250.61%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $3.74
Upside: +434.76%
Sep 27, 2024
Maintains: Sector Outperform
Price Target: $21 → $41
Current: $1.78
Upside: +2,203.37%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $39.59
Upside: +91.97%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $2.57
Upside: +405.84%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $31.58
Upside: +245.16%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $68.25
Upside: +27.47%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $2.11
Upside: +1,463.98%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $0.83
Upside: +4,701.34%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $44.06
Upside: -38.72%
Apr 29, 2020
Maintains: Outperform
Price Target: $89 → $75
Current: $129.35
Upside: -42.02%